Circulation Research. 1996;78:253-261
(Circulation Research. 1996;78:253-261.)
© 1996 American Heart Association, Inc.
Interaction of Cytotoxic T Lymphocytes and Guinea Pig Ventricular Myocytes
Pharmacological Modulation by Blocking K+ Currents in Cytotoxic T Lymphocytes
Bella Felzen,
Revital Lavy,
Maria Garcia,
Gideon Berke,
Phyllis Gardner,
Ofer Binah
From the Rappaport Family Institute for Research in the Medical Sciences
(B.F., R.L., O.B.), Bruce Rappaport Faculty of Medicine, Technion, Haifa,
Israel; Merck Research Laboratories (M.G.), Rahway, NJ; the Department of Cell
Biology (G.B.), Weizmann Institute of Science, Rehovot, Israel; and the
Department of Molecular Pharmacology (P.G.), Stanford (Calif) University
School of Medicine.
Correspondence to Ofer Binah, DSc, Rappaport Institute, PO Box 9697,
Haifa 31096, Israel.
 |
Abstract
|
|---|
Abstract Infiltrating cytotoxic T lymphocytes (CTLs) are
important
immune effectors that damage the myocardium
during heart transplant
rejection as well as in
cardiomyopathy and Chagas' heart disease.
We have
previously shown that in an in vitro model of murine-derived
peritoneal
exudate CTL (PEL)guinea pig ventricular
myocyte interaction,
PEL induced in conjugated myocytes reduction of
resting membrane
potential and action potential (AP) amplitude,
shortening of
AP duration, delayed afterdepolarizations (DADs), and
myocyte
contracture and destruction. Since these findings indicated
that
cytotoxicity was largely caused by
[Ca
2+]
i overload, in the
present study we
tested the hypothesis that blocking the L-type
Ca
2+ current
(I
Ca,L) in the myocyte will eliminate the trigger
for
Ca
2+ release from intracellular stores and will reduce
[Ca
2+]
i overload and subsequent myocyte
deterioration. CoCl
2 (3 mmol/L)
prevented PEL-induced AP
changes, induction of DADs, and myocyte
destruction. Since
verapamil (2 µmol/L) was ineffective,
indicating that the
CoCl
2 protection was not due to block of
I
Ca,L,
we tested whether the different action of
these Ca
2+ channel
blockers was due to their differential
effect on the PEL's K
+ current (I
K),
previously shown to participate in lymphocyte
activation and
cytotoxicity. In agreement with their protective
efficacy,
CoCl
2 but not verapamil blocked I
K
in PELs, suggesting
that this is the mechanism for the protection
provided by CoCl
2.
To support this notion, we tested the
effect of the scorpion-derived
peptide margatoxin (10 nmol/L), a
specific K
+ channel blocker
in lymphocytes, on PEL-myocyte
interaction and on PEL's I
K;
margatoxin prevented
PEL-induced cytotoxicity and also blocked
I
K in PEL. Based
on these findings, an alternative modality
for attenuating CTL-induced
lymphocytotoxicity is proposed.
Key Words: cytotoxic T lymphocytes peritoneal exudate cytotoxic C lymphocytes ventricular myocytes heart transplant rejection Ca2+ channel blockers
 |
Introduction
|
|---|
Cardiac transplantation
is now an accepted treatment for end-stage
myocardial failure, with
the major obstacle to higher survival
rates being the immunological
rejection of the transplanted
heart. Once an allograft is recognized as
nonself, rejection
occurs by means of two pathways, cellular and
humoral, which
operate in concert to destroy foreign tissues. The
cellular
reaction is initiated mostly by helper T (CD4
+)
lymphocytes,
which were initially sensitized by the graft antigens
(mainly
major histocompatibility complex class II) brought to them by
antigen-presenting
cells and by the donor
endothelium. Once sensitized, helper
T lymphocytes
trigger the production of allograft-specific CTLs,
which
then destroy the nonself tissues. At the same time, helper
T
lymphocytes recruit macrophages into the rejection site by
releasing
various cytokines. In turn, macrophages
release interleukin-1,
which further stimulates the system by promoting
interleukin-2
production by T lymphocytes. The allospecific
CTLs then attack
alloantigens, mainly those belonging to the class I
major histocompatibility
complex antigens. Consequently, the cytolytic
machinery is activated,
and the CTLs stage a lethal attack to
destroy donor cells displaying
nonself antigens.
1 2
Lymphocyte-induced damage to the cardiac muscle is not restricted
to heart transplant rejection but is evident in other heart diseases.
It is commonly thought that myocarditis, initiated by a viral
infection, often coxsackievirus B3, may progress in a significant
number of cases to dilated cardiomyopathy. Although
the precise pathological mechanisms of dilated
cardiomyopathy are far from clear, there is a
rather wide agreement that CTL-mediated immune response contributes to
the ongoing cardiac damage, often leading to terminal heart
failure.3 4 5 In addition, CTLs have been
implicated in
myocardial damage induced in Chagas' heart disease in humans and also
in the chronic model of Chagas' heart disease in Trypanosoma
cruziinfected mice.6 7
To understand the precise nature of the interaction of infiltrating
lymphocytes and myocytes during heart transplant rejection as well as
during the course of other heart diseases associated with infiltrating
CTLs, in a recent study we established an in vitro model of interaction
of CTLs and guinea pig ventricular myocytes.8
We used patch-clamp techniques to monitor action potentials and
membrane currents in single ventricular myocytes undergoing
cytocidal interaction with killer lymphocytes. We showed that CTLs
caused general decline in action potential characteristics and in
myocyte contracture; these effects can account, at least in part, for
the decline in cardiac function during heart transplant rejection and
in related heart diseases. On the basis of these findings, we proposed
that cytotoxicity was essentially caused by
[Ca2+]i overload in conjugated myocytes.
In spite of inherent limitations of an isolated CTL-myocyte conjugate
as a model of CTL-mediated heart diseases, it is currently the only
experimental model enabling
electrophysiological recordings
from an "identified" CTL-myocyte conjugate undergoing cytocidal
interaction.8 Therefore, we thought that this model was a
valuable tool for investigating drugs that may interfere with the
cytocidal interaction either at the killer and/or at the target
cell site. Because we have previously suggested that PEL-induced damage
is associated with [Ca2+]i overload in
the
myocyte, in the present study we investigated the effects of
Ca2+ channel blockers. We hypothesized that blocking
ICa,L by means of common Ca2+ channel blockers,
such as CoCl2 and verapamil, will eliminate the
main trigger for Ca2+ release from intracellular stores,
mainly the sarcoplasmic reticulum, and will therefore reduce
[Ca2+]i overload and myocyte
deterioration.
 |
Materials and Methods
|
|---|
Preparation of Ventricular Myocytes
Adult guinea pig
ventricular myocytes were obtained
by an enzymatic
dissociation procedure.
9 Guinea pigs (350
to 400 g) were anesthetized
intraperitoneally
with sodium pentobarbital (30
mg/kg). The chest was opened,
and the heart was rapidly removed,
cannulated through the aorta,
and perfused with modified Tyrode's
solution in a Langendorff
apparatus. After washing out the
blood, the heart was perfused
with 50 mL of nominally
Ca
2+-free Tyrode's solution. Subsequently,
Ca
2+-free
Tyrode's solution containing 0.04% to 0.05%
collagenase (Worthington
Biochemical Corporation) was
circulated for 25 to 35 minutes.
Thereafter, the heart was perfused
with 50 mL of KB medium.
9 All solutions were
oxygenated and warmed to 36.0±0.2°C.
Finally, the heart
was removed from the cannula and placed in
KB medium, and then the
suspension was filtered through a nylon
mesh and stored in KB medium at
room temperature (24.0°C
to 25.0°C) before the experiment. The
modified Tyrode's
solution contained (mmol/L) NaCl 140, KCl 4,
CaCl
2 1.8, MgCl
2 1, glucose 10, and HEPES 5.
The KB medium contained (mmol/L)
KCl 70, K
2HPO
4
30, MgSO
4 5, CaCl
2 0.12, glucose 20, taurine
20,
succinic acid 5, pyruvic acid 5, creatine 5, Na
2ATP 5,
and EGTA
1.
Electrophysiological
Recordings
After 1 to 2 hours of incubation in KB medium, myocytes
were
transferred to the recording chamber (0.5 mL), which was
mounted on the stage of the inverted microscope (Zeiss IM). The bath
was superfused with Tyrode's solution at a rate of 1 to 2 mL/min, and
all experiments were carried out at room temperature (24.0°C to
25.0°C). Membrane potentials and currents were measured by means of
the whole-cell recording technique10 with an
EPC-7 (List Medical Electronics) or Axon 200A (Axon Instruments, Inc)
patch-clamp amplifier. Electrodes were prepared from glass
micropipettes (H15/10, Jencons Scientific), pulled on a vertical puller
(Narashige PP-83), and had a tip resistance of 2 to 4 M
when filled
with the pipette solution containing (mmol/L) potassium aspartate 120,
KCl 20, MgCl2 3.5, KH2PO4 20,
Na2ATP 3, glucose 10, and EGTA 1.
PELs
In vivo primed PELs were obtained from BALB/c mice 4 to
5 days
after the secondary intraperitoneal immunization
with 25x106 C57BL leukemia EL4
cells.11 At the day of the experiment, mice were killed by
cervical dislocation, and peritoneal exudates were obtained by rinsing
the peritoneal cavities with PBS containing 10%
heat-inactivated NCS. The peritoneal exudate cells were
centrifuged, resuspended in RPMI+NCS+HEPES (10 mmol/L), and
incubated in Petri dishes at 37.0°C to cause adherence of B cells and
macrophages to the plastic. After 60 minutes, the nonadherent
cells (PELs) were centrifuged again, then eluted by
RPMI+NSC+HEPES, and kept on ice. The cellular composition and
surface
markers (analyzed by FACS) of PELs are as follows: small to
medium-sized lymphocytes (91%), histiocytes (<2%), and
polymorphonuclear cells (<2%); Thy 1.2 (95%), Lyt-2 (82%), and
L3T4 (19%).12 13 All procedures for handling animals
were
in accordance with institutional guidelines.
The Experimental Model: Conjugate Formation Between Myocytes
and CTLs
CTL-myocyte conjugates were formed between mouse BALB/c
anti-EL4
CTLs (PELs) and guinea pig ventricular myocytes pretreated
with the plant lectin Con A before exposure to PELs. The
sugar-binding lectin "bridges" over the specific recognition
step between the killer and the xenogeneic (guinea pig)
myocytes.14 After obtaining control measurements from a
nonconjugated myocyte, flow to the bath was stopped, and Con A was
added to a final concentration of 10 µg/mL. Ten minutes later, a drop
(10 to 20 µL) of PEL suspension was added to the bath, resulting in
myocytes to which several PELs were attached (see Fig 1A
). That
PELs
and myocytes were firmly bound (ie, conjugated) was verified by gently
moving the recording pipette in the bath; in the presence of
Con A, PELs strongly adhered to the "cruising" myocyte; in its
absence, the lymphocyte detached.


View larger version (57K):
[in this window]
[in a new window]
|
Figure 1. Morphological (A) and
electrophysiological (B) changes in Con
Atreated myocytes conjugated with PELs. A, Photographs obtained
immediately upon conjugate formation (0 minutes, a) and at 15 (b) and
55 (c) minutes thereafter. B, Changes with time in action potential
configuration. Action potential recordings are shown in a
nonconjugated myocyte in Tyrode's solution containing 10 µg/mL Con A
(a) and in a Con Atreated myocyte conjugated with PEL (b). The
progression of the cytocidal interaction was associated with delayed
afterdepolarizations (indicated by arrows). Conjugates were formed by
the addition of PELs to the recording bath containing myocytes
bathed in Tyrode's solutions containing 10 µg/mL Con A. In panel B,
the cycle length was 5 seconds.
|
|
Statistical Analysis
Results are expressed as
mean±SEM. To compare means of two
populations, we used Student's t test for paired or
unpaired observations.
 |
Results
|
|---|
Morphological and Electrophysiological
Alterations in Myocytes Conjugated With PELs: Effects of
CoCl2 and Verapamil
The morphological and
electrophysiological alterations in
myocytes
conjugated with PELs have been reported
previously,
8 with the
major morphological change being
progressive shortening, culminating
in hypercontracture and destruction
(Fig 1A

). We evaluated these
changes by two
morphological markers: (1) the first indication
of myocyte shortening,
28.9±2.8 minutes after formation
of conjugates (n=13), and (2)
myocyte
destruction, 43.5±4.3
minutes after conjugate formation. Such
morphological deterioration
may reflect CTL-induced myocardial damage.
Fig 1B

depicts typical
changes in the action potential of a
conjugated
myocyte. While
the action potential was stable for the entire duration
of the
experiment (60 minutes) in a nonconjugated Con Atreated
myocyte
(or in myocytes exposed to PELs in the absence of Con A [not
shown]),
the action potential was severely altered in conjugated
myocytes,
as indicated by reductions in V
m and APA, a
marked shortening
of APD, and attenuation of the plateau. Frequently,
these alterations
were associated with delayed afterdepolarizations
(shown by
the arrows), indicative of
[Ca
2+]
i
overload. PEL-induced changes
in action potential characteristics are
summarized in the Table

.
To test the hypothesis that
blocking ICa,L, which
triggers Ca2+ release from the sarcoplasmic reticulum, will
reduce [Ca2+]i overload and the
subsequent
cytocidal damage, we determined whether the potent Ca2+
channel blocker CoCl2, recently found to attenuate
the lytic effects of CTL lytic granules on ventricular
myocytes,15 can modify PEL-myocyte cytocidal interaction.
In control experiments, we determined the effect of CoCl2
(3 mmol/L) on action potential characteristics of nonconjugated
myocytes (Fig 2A
, upper trace) and found, as expected,
that CoCl2 attenuated the plateau and shortened APD. As
shown in the Table
, whereas Vm and APA were
unchanged
during 60 minutes of superfusion with CoCl2,
APD50 was reduced. To test the ability of CoCl2
to modulate PEL-myocyte cytocidal interaction, the drug was introduced
to the superfusate immediately after the addition of PELs
and conjugate formation and remained in the bath for the entire
duration of the experiment. This procedure was used to prevent a
possible effect of CoCl2 on conjugate formation. As seen by
the representative recordings in Fig 2A
(lower
trace), the action potential of the CoCl2-treated
conjugated myocyte is indistinguishable from that of
CoCl2-treated nonconjugated myocyte, indicating that
CoCl2 provided considerable protection to the conjugated
myocyte. Aside from the expected APD shortening by CoCl2 in
the conjugated myocyte (as in the nonconjugated myocyte),
Vm and APA were not reduced, the plateau was not abolished
(compare with Fig 1B
) (summarized in the Table
),
and most important,
delayed afterdepolarizations were not induced. In agreement with these
findings, PEL-induced myocyte contracture and destruction did not occur
in CoCl2-treated conjugated myocytes.


View larger version (22K):
[in this window]
[in a new window]
|
Figure 2. Effect of CoCl2 (A) and
verapamil (B) on action potentials of nonconjugated (upper
traces) and ventricular myocytes conjugated to PELs (lower
traces). Action potential recordings are shown in drug-free
Tyrode's solution (0 minutes) and at 60 minutes after addition of the
drug to the superfusate. In experiments with conjugated
myocytes, the drug was added to the Tyrode's solution immediately
after the addition of PELs to the bath and conjugate formation (see
text for details). Cycle length was 5 seconds.
|
|
To determine whether
the protective potency of CoCl2 was
due to a block of ICa,L, we tested whether
verapamil (2 µmol/L), another Ca2+ channel
blocker, had a comparable protective effect. Unlike
CoCl2, verapamil failed to protect
myocytes against killer lymphocytes (Fig 2B
and
Table
), and action
potential deterioration occurred as under drug-free conditions.
Accordingly, verapamil did not prevent the induction of
delayed afterdepolarizations (Fig 2B
, lower trace) or myocyte
contracture and destruction, indicating that ICa,L was not
directly involved in the damage induced in myocytes by killer
lymphocytes.
Changes in IK During PEL-Myocyte Interaction: Effect of
CoCl2
Marked APD shortening and attenuation of the plateau
are the major
electrophysiological alterations in
conjugated myocytes. Hence, we addressed two related questions: (1)
Does an increase in IK (affecting the plateau and
repolarization of the action potential) in conjugated myocytes
contribute to the above changes in action potential? (2) Did
CoCl2 prevent the changes in action potentials of
conjugated myocytes because of its effect on IK per se? In
other words, can a direct inhibitory effect of
CoCl2 on IK potentially oppose a PEL-induced
([Ca2+]i-dependent) increase in
IK? Theoretically, it can be argued that experiments
testing the effect of CoCl2 on IK could have
been more conclusive if performed with conjugated myocytes rather than
with nonconjugated myocytes; however, we chose the second option, since
the possibility of an "indirect" effect of CoCl2 on
IK (in myocytes), mediated through the drug's effect on
the lymphocyte, could not be excluded. Fig 3A
depicts
representative membrane currents in a nonconjugated
myocyte at 0 and 60 minutes (after the beginning of the experiment);
these experiments served as the control for testing the changes in
IK in conjugated myocytes. To prevent a possible effect on
the cytocidal process (in the myocyte and/or the lymphocyte), we did
not use ion channel blockers (eg, tetrodotoxin) or ion-substitution
protocols in order to obtain "pure" IK. The decline
in IK with time seen in this experiment probably resulted
from the natural current "run-down," commonly occurring with
other currents (eg, ICa,L). A summary of the decline in
IK over time (0 to 60 minutes) in nonconjugated myocytes is
depicted by IK I-V relations (Fig 3B
). In contrast
to the
moderate decline seen in control experiments, in conjugated myocytes
(Fig 3B
), the interaction with PELs resulted in a marked
increase in
IK, which can account, at least in part, for APD
shortening and for the plateau attenuation. The mechanism responsible
for the increase in IK in conjugated myocytes was not
explored directly in the present study. We next addressed the
second question, testing whether CoCl2 affects
IK in nonconjugated myocytes. As seen by the
representative membrane currents (Fig 4A
) and by the I-V
relations (Fig 4B
),
CoCl2 only minimally affected IK.


View larger version (41K):
[in this window]
[in a new window]
|
Figure 3. Changes with time in IK in nonconjugated
and conjugated myocytes. A, Representative membrane
current (IM) in nonconjugated myocytes at 0 and 60
minutes in Tyrode's solution. B, IK I-V relations
(IK measured at 5 seconds) at 0, 10, 30, and 60 minutes in
nonconjugated (left) and conjugated (right) myocytes. The holding
potential was -80 mV, the voltage-clamp pulses ranged from
-20 to +60 mV at 10-mV intervals, and the interpulse interval was
7 seconds.
|
|


View larger version (42K):
[in this window]
[in a new window]
|
Figure 4. Effect of CoCl2 on IK in
nonconjugated myocytes. A, Representative membrane
current (IM) at 0 and 10 minutes in Tyrode's
solution. B, IK I-V relations (IK was measured
at 5 seconds) (n=5 myocytes) at 0 (control), 10, 30, and 60 minutes in
CoCl2. The holding potential was -80 mV, the
voltage-clamp pulses ranged from -20 to +60 mV at 10-mV
intervals, and the interpulse interval was 7 seconds.
|
|
Effects of Verapamil and CoCl2 on
IK in PELs
The observation that two potent
Ca2+ channel blockers,
CoCl2 and verapamil, differed markedly in their
ability to interfere with PEL-induced cytotoxicity implied that a block
of ICa,L in conjugated myocytes is unlikely to provide
protection against the cytotoxic damage. This observation, along with
the finding that IK, which is markedly increased in
conjugated myocytes, is also not a target for CoCl2,
suggested that the protection provided by CoCl2 may have
been due to the drug's effect on membrane currents of the killer
lymphocyte. Ideally, testing the effect of CoCl2 on PEL
currents should have been performed on active lymphocytes conjugated to
a myocyte; however, since in every experiment, several lymphocytes
adhered to a myocyte (Fig 1A
), it could not be determined
whether
a randomly monitored PEL is indeed the one killing the myocyte.
Furthermore, it is extremely difficult (if not impossible) to determine
how the presence of a patch electrode on the lymphocyte and dilution of
the lymphocyte intracellular content affect the cytotoxic process. To
bypass this uncertainty, experiments were performed on nonconjugated
PELs. Typical PEL whole-cell membrane currents are depicted in Fig
5A
. The expansion of the first 5 milliseconds (Fig
5B
)
demonstrates that the membrane current closely resembles common
IK, with a relatively rapid onset and
voltage-dependent kinetics. The I-V relations of current measured
at 22 milliseconds are depicted by the open circles in Fig 6
.

View larger version (18K):
[in this window]
[in a new window]
|
Figure 5. A, Typical membrane current (IM)
in PELs. B, The first 5 milliseconds of the current shown in panel A.
The holding potential was -50 mV, the voltage-clamp pulses
ranged from -20 to +60 mV in 10-mV intervals, and the interpulse
interval was 20 seconds.
|
|
Since a variety of membrane currents, and specifically
K+
currents, have been associated with lymphocyte activation and
proliferation,16 17 18 it was of
importance to determine
whether the ability of CoCl2 and the inability of
verapamil to protect myocytes coincide with their effects
on PEL membrane currents. As seen by the effect of both drugs on the
I-V relations (Fig 6
), whereas verapamil was practically
ineffective, CoCl2 almost completely blocked IK
in PELs, providing a plausible explanation for the drug's ability to
protect myocytes against PEL-induced cytotoxic damage.
Margatoxin Protects Conjugated Myocytes and Blocks IK
in PELs
Because the above experiments suggested that blocking
IK in PELs prevented damage induced by the lymphocytes, we
used margatoxin, a specific blocker of IK in T lymphocytes.
Margatoxin, a peptide isolated from the venom of the scorpion
Centruroides margaritatus, has been shown to block cloned
rat Kv1.3 channels19 20 as well as
IK in PEL hybridomas (O. Binah, P. Gardner, unpublished
data, 1995). First, we tested whether margatoxin has a protective
effect comparable to that of CoCl2. As seen in Fig 7
(and summarized in the Table
), the presence of 10
nmol/L margatoxin (a concentration previously shown to block
IK) prevented the typical PEL-induced deterioration in
action potential characteristics and the induction of delayed
afterdepolarizations. Margatoxin also prevented myocyte contracture. To
exclude an effect of margatoxin (at 10 nmol/L) on myocytes that might
be related to its protective efficacy, we determined whether margatoxin
affects the action potential or membrane current of nonconjugated
myocytes. At the same concentration that margatoxin blocked PEL-induced
damage, it did not affect action potential characteristics
(Table
) or
IK (Fig 8
). Finally, we determined whether
the protective capacity of margatoxin corresponds with its ability to
block IK in PEL (Fig 9
). As anticipated,
margatoxin blocked IK almost completely in PELs, leaving a
small current component, most likely due to a "leakage current."
Therefore, this observation strongly supports the findings with
CoCl2 (and verapamil) suggesting that blocking
IK in PELs prevents delivery of the cytotoxic message (ie,
the "lethal hit") to the myocyte.

View larger version (7K):
[in this window]
[in a new window]
|
Figure 7. Effect of margatoxin (10 nmol/L) on action potential
of a conjugated ventricular myocyte. Action potential
recordings are shown in drug-free Tyrode's solution (0
minutes) and at 10, 30, and 60 minutes after the addition of margatoxin
to the superfusate. Cycle length was 5 seconds.
|
|


View larger version (41K):
[in this window]
[in a new window]
|
Figure 8. Effect of margatoxin on IK in
nonconjugated ventricular myocytes. A,
Representative membrane current (IM)
in Tyrode's solution (control, left) and 10 minutes after the addition
of margatoxin (10 nmol/L) to the superfusate (right). B,
IK I-V relations (current measured at 5 seconds) in
Tyrode's solution (0 minutes) and at 10, 30, and 60 minutes after the
addition of margatoxin to the superfusate. The holding
potential was -80 mV, the voltage-clamp pulses ranged from
-20 to +60 mV at 10-mV intervals, and the interpulse interval was
7 seconds.
|
|
 |
Discussion
|
|---|
The experimental model of CTL-myocyte interaction was developed
in
order to investigate the cellular mechanism(s) responsible
for
myocardial damage induced by infiltrating lymphocytes during
the
immunological rejection of transplanted hearts. This model
is also
relevant to other heart diseases associated with CTL
infiltration, such
as viral myocarditis and Chagas' disease.
Since attenuating CTL
cytotoxicity (ie, "immunosuppression")
is a major goal in
retarding lymphocyte-mediated immunopathology,
our overall
objective was to determine whether the damage induced
by CTL to
myocytes can be modulated by pharmacological modification
of membrane
currents in conjugated myocytes and/or in CTL. Heart
transplant
rejection is a complex multifactorial process that
cannot be duplicated
reproducibly in vitro by an isolated CTL-myocyte
conjugate.
Nonetheless, it is presently a unique (and only)
experimental model
enabling whole-cell recordings from a single
conjugated
myocyte undergoing cytocidal interaction with a killer
lymphocyte.
Regarding the fact that we have studied cellular
(xenogeneic)
interaction between BALB/c anti-EL4 PELs and Con
Atreated guinea pig
ventricular myocytes, to the best
of our knowledge, all
evidence supports the view that CTLs use
similar mechanisms to lyse
allogeneic and xenogeneic target
cells, either mediated by lectin (eg,
Con A) or not.
11 Additionally,
with the growing demand for
clinical xenografts, the present
system offers important
information in a field of increasing
interest. The major findings were
as follows: (1) CoCl
2 and
margatoxin, but not
verapamil, prevented PEL-induced changes
in action
potential and myocyte destruction. (2) Since CoCl
2 and
verapamil, both potent I
Ca,L blockers, differed
in their
protective potency, this protection was not due to a block of
I
Ca,L in ventricular myocytes. (3) None of the
drugs tested affected
I
K in myocytes. (4) In agreement with
their protective efficacy,
CoCl
2 and margatoxin, but not
verapamil, blocked I
K in the killer
lymphocyte,
suggesting that this is the mechanism for the protection
provided by
CoCl
2 and margatoxin. Based on these findings, an
alternative
modality for attenuating cellular cytotoxicity, namely,
immunosuppression,
should be examined in future studies.
We have recently reported that PEL-myocyte interaction results in a
reduction in Vm, APA, and APD, as well as
contracture and cell destruction. We concluded that some effects may be
accounted for by [Ca2+]i overload. We
suggested that the marked APD shortening could result from (1)
[Ca2+]i-dependent increase in the
repolarizing outward current, IK,21 and (2)
decreased ICa,L resulting from Ca2+-dependent
inactivation.22 In the present study, we demonstrated
that PEL-myocyte interaction was associated with a marked increase in
IK, probably caused by increased
[Ca2+]i. The possibility that APD
shortening
was due to Ca2+-dependent ICa,L inactivation is
less likely, since shortening occurred in the presence of
verapamil and in the notable absence of
ICa,L.
Our original working hypothesis was that blocking ICa,L
will attenuate PEL-induced damage to conjugated myocytes as a result of
decreased [Ca2+]i overload. That this
assumption was incorrect was suggested by the findings that two potent
Ca2+ channel blockers differed in their ability to protect
myocytes; although verapamil was ineffective,
CoCl2 provided significant protection. We then concluded
that the conjugated myocyte was not the target for the protective
action of CoCl2 and directed our experiments to the
lymphocyte. Under normal experimental conditions, we recorded one
type of membrane current in PEL, which is characterized by
rapid-onset voltage-dependent kinetics and the absence of
inactivation (even at pulses of 200-millisecond duration [not
shown]). We found that in complete agreement with the drug's
ability
(or inability) to protect conjugated myocytes, PEL membrane current,
carried mainly by IK, was blocked by
CoCl2 but not by verapamil. Although we have
not carried out a comparative analysis of the current
characteristics, of the three known types of IK in
lymphocytes, the current sensitivity to CoCl2 and
margatoxin and insensitivity to verapamil suggest that it
is the l-type
IK.16 17 18 23
Having found that blocking IK in PELs prevented damage to
conjugated myocytes, we tested the protective efficacy of margatoxin, a
specific K+ channel blocker in
lymphocytes.24 25 26 As anticipated from
previous reports,
margatoxin blocked IK in PELs and provided complete
protection to conjugated myocytes. At the same time, margatoxin did not
affect the action potential or IK of nonconjugated
myocytes, suggesting that the myocyte was not the target for the
protective action of margatoxin. Margatoxin is a 39amino-acid
peptide toxin recently isolated from the New World scorpion
Centruroides margaritatus, and its primary structure has
been determined.26 27 Margatoxin is structurally
related
to other well-known scorpion toxins and displays 44% sequence
identity with charybdotoxin, 41% with iberiotoxin, and 79% with
noxiustoxin. Previous studies have shown that margatoxin blocks
voltage-dependent Kv1.3 current in human peripheral T
lymphocytes with high affinity (half block at
50
pmol/L)27 and has no effect on the small-conductance
Ca2+-activated K+ channels in human T
lymphocytes.24 In smooth muscle sarcolemma, margatoxin,
unlike charybdotoxin, is inactive on the high-conductance
Ca2+-activated K+ channel even at 1
µmol/L.27
Why Does Blocking IK in Killer Lymphocytes Prevent the
Cytotoxic Damage to Conjugated Myocytes?
The involvement of different
ion channels in T-lymphocyte
activation and proliferation is well
established,16 17 18 but
less is known about the role of ion channels in cytotoxic function.
Several observations suggest that K+ currents are involved
in cytotoxicity. 86Rb efflux from CTLs was increased under
conditions of specific target cell lysis.28 Pretreatment
of natural killer cells with quinidine,
4-aminopyridine, verapamil, and
CdCl2, at concentrations that block K+
channels, inhibited the killing of target cells.29
Similarly, the K+ channel blockers quinidine and
4-aminopyridine inhibited target cell lysis by
lymphokine-activated killer cells.30 Strong
support for the involvement of K+ channels in lymphocyte
activation and cytotoxic function comes from a recent study testing the
effects of margatoxin in human T lymphocytes.24 At
concentrations at which margatoxin blocked voltage-dependent
K+ channels in lymphocytes (0.5 to 5 nmol/L), the toxin
inhibited interleukin-2 production of ionomycin+phorbol
12-myristate 13-acetatestimulated T lymphocytes, as well
as the anti-CD3induced rise in
[Ca2+]i.
These observations strongly support the findings of the present
work, ie, that blocking IK prevented killer lymphocyte
activation and delivery of the lethal hit to the target cell. Finally,
it should be noted that at present the precise role of
K+ channels in lymphocyte activation and cytotoxic function
is not entirely clear. Since depolarizing the cell with high external
K+ enhanced killing whereas hyperpolarizing the cell with
valinomycin or low external K+ inhibited killing, the
primary role of K+ channels is probably not only to
maintain a negative resting potential.31 Thus, although
there is a correlation between K+ channel blockade and
inhibition of lymphocytotoxicity, the mechanism(s) whereby
K+ channels are involved in killing is yet to be
determined.18
In summary, we investigated the cytocidal
interaction of PELs and
ventricular myocytes and demonstrated that blocking
IK in PELs by CoCl2 and margatoxin prevented
PEL-induced damage to the myocytes. This pharmacological modulation of
lymphocytotoxicity in vitro can be considered a potential modality for
a novel immunosuppression therapy.
 |
Selected Abbreviations and Acronyms
|
|---|
| APA |
= |
action potential amplitude |
| APD |
= |
action potential duration |
| APD50 |
= |
APD at 50% repolarization |
| Con A |
= |
concanavalin A |
| CTL |
= |
cytotoxic (killer) T lymphocyte |
| I-V |
= |
current-voltage |
| ICa,L |
= |
L-type Ca2+ current |
| IK |
= |
delayed outward K+ current |
| KB |
= |
Kraftbrühe |
| NCS |
= |
newborn calf sera |
| PEL |
= |
peritoneal exudate CTL |
| Vm |
= |
resting membrane potential |
|
 |
Acknowledgments
|
|---|
This study was supported by grants to Drs Binah and Berke from
the
US-Israel Binational Science Foundation, the Israeli Ministry
of
Health, the Minerva Foundation through the Bernard Katz Center
for Cell
Biophysics, and the German Cancer Center, Heidelberg.
The research was
also supported by the Rappaport Family Institute
for Research in the
Medical Sciences and by a grant to Dr Gardner
from the American Cancer
Society (DB26E).
Received May 5, 1995;
accepted October 31, 1995.
 |
References
|
|---|
-
Auchincloss HD, Sachs H. Transplantation
and graft rejection. In: Paul WE, ed. Fundamental
Immunology. New York, NY: Raven Press Publishers; 1989:889-922.
-
Binah O. Immune effector mechanisms in heart
transplant rejection. Cardiovasc Res. 1994;28:1748-1757. [Abstract/Free Full Text]
-
Leslie K, Blay R, Haisch C, Lodge A, Weller A, Huber
S. Clinical and experimental aspects of viral
myocarditis. Clin Microbiol Rev. 1989;2:191-203. [Abstract/Free Full Text]
-
Seko Y, Shinkai Y, Kawasaki A, Yagita H, Okumura K,
Takaku F, Yazaki Y. Expression of perforin in infiltrating cells
in murine hearts with acute myocarditis caused by coxsackievirus
B3. Circulation. 1991;84:788-795. [Abstract/Free Full Text]
-
Huber SA, Morasaka A, Choate M. T cells
expressing the

T-cell receptor potentiate coxsackievirus
B3-induced myocarditis. J Virol. 1992;66:6541-6546. [Abstract/Free Full Text]
-
Brener Z. Pathogenesis and immunopathology of
chronic Chagas' disease. Mem Inst Oswaldo Cruz. 1987;82:205-213.
-
Morris SA, Tanowitz HB, Wittner M, Bilezikian
JP. Pathophysiological insights into the
cardiomyopathy of Chagas' disease.
Circulation. 1990;82:1900-1909. [Abstract/Free Full Text]
-
Felzen B, Berke G, Rosen D, Binah O. Mechanisms
whereby cytotoxic T lymphocytes damage guinea pig
ventricular myocytes. Pflugers Arch. 1994;427:422-431. [Medline]
[Order article via Infotrieve]
-
Isenberg G, Klockner U. Calcium tolerant
ventricular myocytes prepared by preincubation in a `KB
medium.' Pflugers Arch. 1982;395:6-18. [Medline]
[Order article via Infotrieve]
-
Hamill OP, Marty A, Neher E, Sakmann B, Sigworth
FJ. Improved patch-clamp techniques for high resolution
recording from cells and cell-free membrane
patches. Pflugers Arch. 1981;391:85-100.[Medline]
[Order article via Infotrieve]
-
Berke G, Sullivan KA, Amos DB. Rejection of
ascites tumor allografts, l: isolation, characterization and
in vitro reactivity of peritoneal lymphoid effector cells
from BALB/c mice immune to EL4 leukosis. J Exp
Med. 1972;135:1334-1350. [Abstract]
-
Berke G. Interaction of cytotoxic T lymphocytes
and target cells. Prog Allergy. 1980;27:68-133.
-
Berke G, Rosen D. Highly lytic in vivo primed
CTL devoid of lytic granules and BLT-esterase activity acquire these
constituents in the presence of growth factors upon blast
transformation in vivo. J Immunol. 1988;141:1429-1436. [Abstract]
-
Sharon N, Lis A. Lectins as cell recognition
molecules. Science. 1989;246:227-233. [Abstract/Free Full Text]
-
Binah O, Berke G, Rosen D, Hoffman B. Calcium
channel blockers modify
electrophysiological effects of lytic
granules from cytotoxic T lymphocytes in guinea pig
ventricular myocytes. J Pharmacol
Exp Ther. 1994;268:1581-1587. [Abstract/Free Full Text]
-
Gallin EK. Ion channels in leukocytes.
Pharmacol Rev. 1991;71:775-811.
-
Lewis RS, Cahalan MD. Ion channels and signal
transduction in lymphocytes. Annu Rev Physiol. 1990;52:415-430. [Medline]
[Order article via Infotrieve]
-
Premack BA, Gardner P. Role of ion channels in
lymphocytes. J Clin Immunol. 1991;11:225-238. [Medline]
[Order article via Infotrieve]
-
Grissmer S, Dethlefs B, Wasmuth JJ, Goldin AL, Gutman
G, Cahalan MD, Chandy KG. Expression and chromosomal
localization of a lymphocyte channel gene. Proc Natl Acad
Sci U S A. 1990;87:9411-9415. [Abstract/Free Full Text]
-
Novick J, Leonard RJ, King VF, Schmalhofer W,
Kaczorowski GJ, Garcia ML. Purification and characterization of
two novel peptidyl toxins directed against K+ channels from
the venom of new world scorpions. Biophys J. 1991;59:78. Abstract.
-
Toshe N. Calcium sensitive delayed rectifier
potassium current in guinea pig ventricular cells.
Am J Physiol. 1990;258:H1200-H1207. [Abstract/Free Full Text]
-
Kokubun S, Irisawa H. Effects of various
intracellular Ca ion concentrations on the calcium current of guinea
pig ventricular cells. Jpn J Physiol. 1984;34:599-611. [Medline]
[Order article via Infotrieve]
-
Decoursey TE, Chandy KG, Gupta S, Cahalan MD.
Mitogen induction of ion channels in murine lymphocytes.
J Gen Physiol. 1987;89:405-420. [Abstract/Free Full Text]
-
Leonard RJ, Garcia ML, Slaughter RS, Reuben JP.
Selective blockers of voltage-gated K+ channels
depolarize human T lymphocytes: mechanism of antiproliferative effect
of charybdotoxin. Proc Natl Acad Sci U S A. 1992;89:10094-10098. [Abstract/Free Full Text]
-
Lin CS, Boltz RC, Blake JT, Nguyen M, Talento A,
Fischer PA, Springer MS, Sigal NH, Slaughter RS, Garcia ML, Kaczorowski
J, Koo GC. Voltage-gated potassium channels regulate
calcium-dependent pathways involved in human T lymphocyte
activation. J Exp Med. 1993;177:637-645. [Abstract/Free Full Text]
-
Bednarek MA, Bugianesi RM, Leonard RJ, Felix JP.
Chemical synthesis and structure function studies of margatoxin, a
potent inhibitor of voltage-dependent potassium channel
in human T lymphocytes. Biochem Biophys Res Commun. 1994;198:619-625. [Medline]
[Order article via Infotrieve]
-
Garcia-Calvo M, Leonard RJ, Novick J, Stevens SP,
Schmalhofer W, Kaczorowski GJ, Garcia ML. Purification,
characterization, and biosynthesis of margatoxin, a component
of Centruroides margaritatus venom that selectively
inhibits voltage-dependent potassium channels. J
Biol Chem. 1993;268:18866-18874. [Abstract/Free Full Text]
-
Russel JH, Dubos CB. Accelerated
86Rb (K+) release from cytotoxic T lymphocytes
is a physiologic event associated with delivery of the lethal
hit. J Immunol. 1983;131:1138-1141. [Abstract]
-
Schlichter LN, Sidell N, Hagiwara S. Potassium
channels mediate killing in human natural killer cells.
Proc Natl Acad Sci U S A. 1986;137:1650-1658.
-
Lefever A, Liepins A, Truit R. Role of
K+ ion channels in lymphokine-activated killer
(LAK) cell lytic function. Immunopharmacol
Immunotoxicol. 1989;11:571-582. [Medline]
[Order article via Infotrieve]
-
Schlichter LC, MacCourbey IC. Interactive
effects of Na and K in killing by human natural killer cells.
Exp Cell Res. 1989;184:99-108. [Medline]
[Order article via Infotrieve]
This article has been cited by other articles:

|
 |

|
 |
 
G. Panyi, G. Vamosi, Z. Bacso, M. Bagdany, A. Bodnar, Z. Varga, R. Gaspar, L. Matyus, and S. Damjanovich
Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells
PNAS,
February 3, 2004;
101(5):
1285 - 1290.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sasayama, A. Matsumori, and Y. Kihara
New insights into the pathophysiological role for cytokines in heart failure
Cardiovasc Res,
June 1, 1999;
42(3):
557 - 564.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Felzen, M. Shilkrut, H. Less, I. Sarapov, G. Maor, R. Coleman, R. B. Robinson, G. Berke, and O. Binah
Fas (CD95/Apo-1)–Mediated Damage to Ventricular Myocytes Induced by Cytotoxic T Lymphocytes From Perforin-Deficient Mice : A Major Role for Inositol 1,4,5-Trisphosphate
Circ. Res.,
March 9, 1998;
82(4):
438 - 450.
[Abstract]
[Full Text]
[PDF]
|
 |
|